Clinical trial
A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line…
NCT00118755 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00118755 |
|---|---|
| Title | A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer |
| Official title | A Randomized, Open-label Study of the Effect of 2 Different Treatment Schedules of Xeloda With Eloxatin and Avastin on Progression-free Survival in Treatment-naïve Patients With Locally Advanced or Metastatic Colorectal Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, Oxaliplatin, bevacizumab |
| Enrollment | 435 |
| Start date | Jul 1, 2005 |
| Primary completion | Apr 1, 2009 |
| First posted | Jul 12, 2005 |
| Last update posted | Mar 3, 2011 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: